Deep Dive In Vitiligo

A paused drug program. A reasonable suspicion. Then the question under it: why is there still no cure? In this episode, Yan Valle argues there is no hidden pill in a glass tower. Companies are not charities, and they are not sitting on a cure because a chronic treatment pays better. The harder account is ordinary. Academia funds what it can publish. Biotech bets on the next round. Pharma keeps what can survive the regulators and the market. Insurers pay for this year’s budget. Patients inherit the sum. A program can die before anyone knows if the biology was right — a bet on another bet, ten years out, before the casino is built. Early treatment of active vitiligo sounds obvious, and still loses to step therapy and a planning horizon shorter than a child’s year. The price on the receipt was not set by one hand. And “they buried the cure” is easier to air than a system with no villain. Misconduct is real. This is not a defense of it. But systems before conspiracy is usually the better place to start. The full essay is on the VRF site. Ten minutes. A double coffee is welcome.

Your skin may enter the room first. Your job is to make sure your work takes over the conversation. Visible vitiligo does not change competence. It can still change interviews, promotions, and how “professional” gets judged — especially when the face is involved. That is a social problem, not a skills problem. Social problems need strategy, boundaries, and sometimes a little documentation. In this episode we cover the unglamorous playbook: how to build a case instead of a vibe, what to say if someone stares or asks the wrong question, when disclosure helps and when it doesn’t, and which workplace protections may apply in the US and the UK. Bias exists. So do portfolios, notes, and the right to leave. Your skin is not the product. Prefer reading to listening? The companion article expands on the themes in this episode: Career Success with Visible Vitiligo.

Fifteen years ago, keeping up with vitiligo news was easy. There simply wasn’t that much of it. Today, research, clinical trials, industry updates, patient discussions, and AI-generated answers arrive faster than anyone can realistically process them. In Episode 78 of Deep Dive in Vitiligo, we look at what happens next: people stop searching, comparing, and opening twenty browser tabs — and start asking AI to do the thinking for them. That shift has a name: cognitive surrender. We explore why handing part of the decision-making process to ChatGPT and other AI tools can be perfectly rational, where it becomes risky, and why pharma companies, doctors, and patient organizations suddenly need to care about what AI says when someone asks a very simple question: “What are my options?” AI may be both the cause of the information flood and our best tool for navigating it. Just don’t let it out of the fire pit. 📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode. 15 Years of Vitiligo News Publication

What changes when vitiligo puts on a uniform? The disease stays the same. Almost everything around it changes — from medical fitness and deployment to treatment access, military records, VA care, and disability claims. In this episode of Deep Dive in Vitiligo, we follow the patient journey from sick call to civilian care and examine where people, records, and responsibility can fall through the cracks. We also separate three questions that are too often mixed together: Can someone join? Can they remain in service? And did military service cause or aggravate the condition? We close with a preview of Massé World’s Honor Without Exception, a free symposium bringing service members, veterans, clinicians, researchers, and policymakers together in Miramar, Florida, on November 14, 2026. Same skin condition. Different rules. Much higher stakes. 📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.

Durante años, la crema aprobada se detenía a los 12. Los más pequeños se quedaban con el menú de siempre: corticoides, tacrolimus, luz si había hueco, y mucha espera. Eso empieza a cambiar. Hay dos ensayos de fase 3 con crema de ruxolitinib — Opzelura, si ya conoces el tubo — en niños con la forma más común de vitíligo. Protocolos de verdad. Centros de verdad. No un rumor de un grupo de padres. El matiz: no son el mismo estudio. Si los mezclas, una familia reserva viaje al continente equivocado. En este episodio de *Deep Dive in Vitiligo* ponemos los dos ensayos uno al lado del otro. Vas a escuchar: El ensayo norteamericano TRuE-ViP (NCT06548360): de 2 a 11 años, Estados Unidos y Canadá, unos 180 niños El ensayo internacional (NCT06804811, Incyte INCB18424-309): a partir de los 6 años, Argentina más 13 países europeos, unos 250 niños, sin centros en EE. UU. ni Canadá Lo que comparten: solo vitíligo no segmentario, un techo del 10% de superficie corporal, crema vehículo las primeras 24 semanas, la cara como medida principal en la semana 24, y la obligación de pausar otros tratamientos para el vitíligo, incluida la fototerapia Por qué un niño de 8 años puede cumplir la edad en los dos y no encajar en ninguno por código postal No suspendas un tratamiento que ya funciona porque en la misma semana aparecieron dos páginas de ensayo. Pregunta en el centro qué habría que pausar. Después llama al dermatólogo habitual del niño. Sí es una respuesta razonable. No también. La pregunta útil es qué protocolo — si es que alguno — encaja con este niño, en este país, con esta agenda.